Vadadustat
- Generic Name
- Vadadustat
- Brand Names
- Vafseo
- Drug Type
- Small Molecule
- Chemical Formula
- C14H11ClN2O4
- CAS Number
- 1000025-07-9
- Unique Ingredient Identifier
- I60W9520VV
- Background
One of the most common symptoms of advanced renal disease is anemia, caused primarily by the inability of the kidney to respond to anemic conditions with a corresponding increase in erythropoietin (EPO) production. The treatment of anemia associated with chronic kidney disease (CKD) has traditionally involved the administration of exogenous erythropoiesis-st...
- Indication
Vadadustat is indicated for the treatment of symptomatic anemia associated with chronic kidney disease (CKD) in adults on chronic maintenance dialysis.
- Associated Conditions
- Symptomatic Anemia
- Associated Therapies
- -
Vafseo Outcomes In-Center Experience
- Conditions
- Interventions
- First Posted Date
- 2024-07-25
- Last Posted Date
- 2024-12-11
- Lead Sponsor
- USRC Kidney Research
- Target Recruit Count
- 2200
- Registration Number
- NCT06520826
- Locations
- 🇺🇸
Nephrology and Hypertension Specialists, PC, Dalton, Georgia, United States
🇺🇸US Renal Care - Gallup, Gallup, New Mexico, United States
🇺🇸Dallas Renal Group, Dallas, Texas, United States
Study to Evaluate the Safety and Efficacy of Oral Vadadustat in Pediatric Participants With Anemia of Chronic Kidney Disease Naive to Erythropoiesis-Stimulating Agents
- First Posted Date
- 2021-10-19
- Last Posted Date
- 2023-10-10
- Lead Sponsor
- Akebia Therapeutics
- Target Recruit Count
- 71
- Registration Number
- NCT05082584
- Locations
- 🇺🇸
Research Site, Hackensack, New Jersey, United States
Study to Evaluate the Safety and Efficacy of Oral Vadadustat in Pediatric Participants With Anemia of Chronic Kidney Disease
- First Posted Date
- 2021-10-19
- Last Posted Date
- 2023-10-10
- Lead Sponsor
- Akebia Therapeutics
- Target Recruit Count
- 71
- Registration Number
- NCT05082571
- Locations
- 🇺🇸
Research Site, Hackensack, New Jersey, United States
Study to Assess the Safety and Pharmacokinetics of AKB-6548 in Participants With Chronic Kidney Disease (CKD), Stages 3 and 4
- First Posted Date
- 2021-01-13
- Last Posted Date
- 2022-06-28
- Lead Sponsor
- Akebia Therapeutics
- Target Recruit Count
- 22
- Registration Number
- NCT04707573
- Locations
- 🇺🇸
Research Site, Knoxville, Tennessee, United States
Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera®) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects
- Conditions
- Interventions
- First Posted Date
- 2021-01-13
- Last Posted Date
- 2023-12-18
- Lead Sponsor
- Akebia Therapeutics
- Target Recruit Count
- 456
- Registration Number
- NCT04707768
- Locations
- 🇺🇸
Research Site, Woodbridge, Virginia, United States
🇺🇸Research Site#1, Coral Springs, Florida, United States
🇺🇸Research Site#2, Coral Springs, Florida, United States
Vadadustat for the Prevention and Treatment of Acute Respiratory Distress Syndrome (ARDS) in Hospitalized Patients With Coronavirus Disease 2019 (COVID-19)
- Conditions
- Interventions
- First Posted Date
- 2020-07-20
- Last Posted Date
- 2023-02-17
- Target Recruit Count
- 449
- Registration Number
- NCT04478071
- Locations
- 🇺🇸
The University of Texas Health Science Center at Houston, Houston, Texas, United States
Trial Evaluating the Efficacy and Safety of Oral Vadadustat Once Daily (QD) and Three Times Weekly (TIW) for the Maintenance Treatment of Anemia in Hemodialysis Subjects Converting From Erythropoiesis-Stimulating Agents (ESAs)
- First Posted Date
- 2020-03-18
- Last Posted Date
- 2022-11-21
- Lead Sponsor
- Akebia Therapeutics
- Target Recruit Count
- 319
- Registration Number
- NCT04313153
- Locations
- 🇪🇸
Research Site, Valencia, Spain
🇪🇸Research Site #2, Barcelona, Spain
Study in Healthy Adult Subjects to Assess the Effect of Phosphate Binders on the Pharmacokinetics of a Single Dose of Vadadustat
- Conditions
- Interventions
- First Posted Date
- 2020-03-09
- Last Posted Date
- 2020-10-08
- Lead Sponsor
- Akebia Therapeutics
- Target Recruit Count
- 54
- Registration Number
- NCT04299633
- Locations
- 🇨🇦
Research Site, Quebec, Canada
Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Safety of Vadadustat in Hemodialysis Subjects With Anemia Associated With Chronic Kidney Disease
- Conditions
- Interventions
- First Posted Date
- 2019-06-19
- Last Posted Date
- 2020-09-16
- Lead Sponsor
- Akebia Therapeutics
- Target Recruit Count
- 46
- Registration Number
- NCT03992066
- Locations
- 🇺🇸
Research Site, Chattanooga, Tennessee, United States
Drug-Drug Interaction Study of Vadadustat With Cyclosporine, Probenecid and Rifampin
- Conditions
- Interventions
- First Posted Date
- 2019-01-11
- Last Posted Date
- 2019-03-22
- Lead Sponsor
- Akebia Therapeutics
- Target Recruit Count
- 40
- Registration Number
- NCT03801746
- Locations
- 🇨🇦
inVentiv Health Clinique Inc., Québec City, Quebec, Canada
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.